Figure 5.

Inhibiting GLS effectively synergizes with cisplatin to induce colon cancer cell death

(A) DLD-1 cells were transfected with control shRNA or sh-GLS1 for 48 h, followed by treatments of cisplatin at the indicated concentrations. Cell viability was determined by MTT and (B) clonogenic assays. (C) LoVo cells were transfected with control shRNA or sh-GLS1 for 48 h, followed by treatments of cisplatin at the indicated concentrations. Cell viability was determined by MTT and (D) clonogenic assays. (E) DLD-1 cells were treated with BPTES at 0, 25, or 50 nM plus cisplatin at the indicated concentrations. Cell viability and cell death were examined by MTT and (F) annexin V assays. (G) The combination index (CI) was calculated using CompuSyn software based on the results of (E) and (F). (H) LoVo cells were treated with BPTES at 0, 25, or 50 nM plus cisplatin at the indicated concentrations. Cell viability and cell death were examined by MTT and (I) annexin V assays. (J) The CI was calculated using CompuSyn software based on the results of (H) and (I). Data are presented as mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.